O’Connor steps down as CEO of Advaxis

Friday, July 7, 2017

Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of a proprietary Lm-based antigen delivery system, has announced his resignation from the company and its board of directors.

[Read More]

Advaxis initiates combination portion of phase I/II study with Merck & Co.

Monday, October 24, 2016

Advaxis, clinical stage biotechnology company developing cancer immunotherapies, has announced the commencement of Part B of the KEYNOTE-046 clinical trial evaluating Advaxis’ Lm immunotherapy candidate, ADXS-PSA, in combination with KEYTRUDA (pembrolizumab) in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). In Part A of the phase I/II study, 14 patients were treated with ADXS-PSA monotherapy across three dose levels, with no dose limiting toxicities, paving the way for initiating Part B of the study.

[Read More]

Advaxis, Incyte collaborate on early stage cervical cancer immunotherapies

Thursday, February 12, 2015

Advaxis, a Princeton, N.J.-based clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Incyte is a pharmaceutical company based in Alapocas, Del.

[Read More]